Declaration on the Effectiveness of Test Kits against BA.4 and BA.5

Company news
2022-07-01

WHO Director-General Tedros Adhanom Ghebreyesus Ph.D. said on 29 June 2022, COVID-19 cases are rising in 110 countries, driven by BA.4 and BA.5 in many places, causing overall global cases to increase by 20%, and deaths have risen in three of the six WHO regions.

 

The SARS-CoV-2 variants BA.4 and BA.5 were first detected in South Africa in January and February 2022 and became dominant locally in May 2022. As of 12 May 2022, ECDC reclassified Omicron sub-lineages BA.4 and BA.5 from variants of interest to variants of concern. According to the European Centre for Disease Prevention and Control report, most European Union/European Economic Area (EU/EEA) countries have detected the SARS-CoV-2 variants BA.4 and BA.5, and many have seen an increase in recent weeks. In Portugal, for example, BA.5 has become the dominant SARS-CoV-2 variant, and a surge in COVID-19 cases has accompanied the increasing proportions of BA.5. The growth advantage reported for BA.4 and BA.5 suggests that these variants will become dominant throughout the EU/EEA, probably resulting in an increase in COVID-19 cases in the coming weeks. According to the sequences submitted to GISAID, the percentage of BA.4 increased from 9% to 12%, and BA.5 increased from 28% to 43%.

 

The increased infection is due to the ability of BA.4 and BA.5 to evade immune protection against infection induced by prior infection and/or vaccination, particularly if this has waned over time. Based on preliminary in-vitro data from preprints, BA.4 and BA.5 are antigenically distant from the ancestral virus and, compared to BA.1 and BA.2, they are less efficiently neutralized by sera from individuals vaccinated with three doses of COVID-19 vaccine (Vaxzevria or Comirnaty), or by sera from BA.1 vaccine breakthrough infections.

 

For persistent infection, keep testing.

 

Bioperfectus aims to provide our customers with high-quality and reliable total solutions of molecular diagnostics to SARS-CoV-2. We keep closely tracking the reported COVID-19 variants. After analysis and experiment, the performance of our COVID-19 detection products, including SARS-CoV-2 Real-time PCR kits and rapid antigen tests, will not be affected by BA.4 and BA.5. For more information, kindly find the Declaration Letter.

 

Click here to download the Letter of Declaration Rapid Test

Click here to download the Letter of Declaration RT PCR Kit

 

References

MOST READ

Your Problem, Our Solution

At Bioperfectus, the excellent experience of our customers is our goal and the key to our job. Last Wednesday, we completed online technical training for our distribution local support in the Asia Pacific region. The webinar covers insightful training on Bioperfectus Nucleic Acid Extraction System, Nucleic Acid Extraction Kit, Real-Time PCR System, and product demonstration on the newly launched SAW-96 Nucleic Acid Extraction Workstation.

2022-08-16

MHRA Registration Approval for BioPerfectus Monkeypox Virus Real Time PCR Kit

Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “BioPerfectus”) is pleased to announce that Monkeypox Virus Real Time PCR Kit has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and is now officially available for Great Britain and Northern Ireland market.

2022-08-11

A Simplified HPV-DNA Workflow for Better Preventing Cervical Cancer

With over 600 thousand new cases and more than half that would lead to death each year, cervical cancer is listed as the fourth most frequent cancer among women worldwide.

2022-08-05